Inverse association of female hormone replacement therapy with age-related macular degeneration and interactions with ARMS2 polymorphisms

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 4, 2010, Pages 1873-1879

  Edwards, Digna R Velez ^a   Gallins, Paul ^a   Polk, Monica ^a   Ayala Haedo, Juan ^a   Schwartz, Stephen G ^b   Kovach, Jaclyn L ^b   Spencer, Kylee ^c   Wang, Gaofeng ^a   Agarwal, Anita ^c   Postel, Eric A ^d   Haines, Jonathan L ^c   Pericak Vance, Margaret ^a   Scott, William K ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; APOLIPOPROTEIN E; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; ARMS2 PROTEIN, HUMAN; ESTROGEN; ORAL CONTRACEPTIVE AGENT; PROTEIN;

AGE DISTRIBUTION; AGED; ARTICLE; BIRTH CONTROL; CHROMOSOME 10Q; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; GEOGRAPHY; HEREDITY; HORMONE SUBSTITUTION; HUMAN; INTRON; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PRIORITY JOURNAL; REPRODUCTIVE HISTORY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETINA NEOVASCULARIZATION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; VISUAL IMPAIRMENT; ESTROGEN THERAPY; GENETICS; GENOTYPE; QUESTIONNAIRE; RISK;

AGED; CONTRACEPTIVES, ORAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GENOTYPE; HUMANS; MACULAR DEGENERATION; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; QUESTIONNAIRES; REPRODUCTIVE HISTORY;

EID: 77951232154     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4000     Document Type: Article

References (64)

1. Hyman L. Epidemiology of AMD. In: Hampton R, Neslon P, eds. Age-Related Macular Degeneration: Principles and Practice. New York: Raven Press; 1992:1-35.
2. Munoz B, West SK, Rubin GS, et al. Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study. Arch Ophthalmol. 2000;118:819-825.
3. Spencer G. Projections of the population of the United States by age, sex, and race: 1988-1989. Washington, DC: US Bureau of the Census. 1989;P-25:1018.
4. Attebo K, Mitchell P, Smith W. Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996;103:357-364.
5. Klaver CC, Wolfs RC, Assink JJ, et al. Genetic risk of age-related maculopathy: population-based familial aggregation study. Arch Ophthalmol. 1998;116:1646-1651.
6. Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol. 1998;116: 653-658.
7. Tielsch JM, Javitt JC, Coleman A, et al. The prevalence of blindness and visual impairment among nursing home residents in Baltimore. N Engl J Med. 1995;332:1205-1209.
8. Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48:257-293.
9. Sepp T, Khan JC, Thurlby DA, et al. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest Ophthalmol Vis Sci. 2006;47:536-540.
10. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 2001;108:697-704.
11. Spencer KL, Hauser MA, Olson LM, et al. Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. Hum Mol Genet. 2007;16: 1986-1992.
12. Jakobsdottir J, Conley YP, Weeks DE, et al. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet. 2005;77:389-407.
13. Rivera A, Fisher SA, Fritsche LG, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005;14:3227-3236.
14. Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group. Arch Ophthalmol. 1992; 110:1701-1708.
15. Snow KK, Cote J, Yang W, et al. Association between reproductive and hormonal factors and age-related maculopathy in postmenopausal women. Am J Ophthalmol. 2002;134:842-848.
16. The Eye Disease Case-Control Study Group. Risk factors for idiopathic macular holes. Am J Ophthalmol. 1994;118:754-761.
17. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol. 1996;114:545-554.
18. Gray RH, Gregor ZJ, Marsh M. Oestrogens and macular holes: a postal questionnaire. Eye. 1994;8:368-369.
19. Feskanich D, Cho E, Schaumberg DA, et al. Menopausal and reproductive factors and risk of age-related macular degeneration. Arch Ophthalmol. 2008;126:519-524.
20. Fraser-Bell S, Wu J, Klein R, et al. Smoking, alcohol intake, estrogen use, and age-related macular degeneration in Latinos: the Los Angeles Latino Eye Study. Am J Ophthalmol. 2006;141:79-87.
21. Freeman EE, Munoz B, Bressler SB, West SK. Hormone replacement therapy, reproductive factors, and age-related macular degeneration: the Salisbury Eye Evaluation Project. Ophthalmic Epidemiol. 2005;12:37-45.
22. Klein BE, Klein R, Lee KE. Reproductive exposures, incident agerelated cataracts, and age-related maculopathy in women: the Beaver Dam Eye Study. Am J Ophthalmol. 2000;130:322-326.
23. Klein R, Klein BE, Wang Q, Moss SE. Is age-related maculopathy associated with cataracts? Arch Ophthalmol. 1994;112:191-196.
24. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000;107: 2224-2232.
25. Clemons TE, Milton RC, Klein R, et al. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology. 2005;112:533-539.
26. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med. 2002;4: 45-61.
27. Ioannidis JP. Non-replication and inconsistency in the genomewide association setting. Hum Hered. 2007;64:203-213.
28. Snow KK, Seddon JM. Age-related eye diseases: impact of hormone replacement therapy, and reproductive and other risk factors. Int J Fertil Womens Med. 2000;45:301-313.
29. Postel EA, Agarwal A, Schmidt S, et al. Comparing age-related macular degeneration phenotype in probands from singleton and multiplex families. Am J Ophthalmol. 2005;139:820-825.
30. Schmidt S, Saunders AM, De La Paz MA, et al. Association of the apolipoprotein E gene with age-related macular degeneration: possible effect modification by family history, age, and gender. Mol Vis. 2000;6:287-293.
31. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of agerelated maculopathy. Am J Ophthalmol. 1997;123:199-206.
32. Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS): design implications: AREDS report no. 1. Control Clin Trials. 1999;20:573-600.
33. Klein R, Davis MD, Magli YL, et al. The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991;98:1128-1134.
34. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and agerelated macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367-374.
35. Shuler RK Jr, Schmidt S, Gallins P, et al. Phenotype analysis of patients with the risk variant LOC387715 (A69S) in age-related macular degeneration. Am J Ophthalmol. 2008;145:303-307.
36. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419-421.
37. Schmidt S, Hauser MA, Scott WK, et al. Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Genet. 2006;78:852-864.
38. Spencer KL, Hauser MA, Olson LM, et al. Haplotypes spanning the complement factor H gene are protective against age-related macular degeneration. Invest Ophthalmol Vis Sci. 2007;48:4277-4283.
39. Spencer KL, Olson LM, Anderson BM, et al. C3 R102G polymorphism increases risk of age-related macular degeneration. Hum Mol Genet. 2008;17:1821-1824.
40. Spencer KL, Hauser MA, Olson LM, et al. Deletion of CFHR3 and CFHR1 genes in age-related macular degeneration. Hum Mol Genet. 2008;17:971-977.
41. Hancock DB, Martin ER, Li YJ, Scott WK. Methods for interaction analyses using family-based case-control data: conditional logistic regression versus generalized estimating equations. Genet Epidemiol. 2007;31:883-893.
42. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
43. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002;296:2225-2229.
44. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995;273:199-208.
45. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-461.
46. Stefanick ML, Prentice RL, Anderson G, et al. Reanalysis of the Women's Health Initiative oral contraceptive data reveals no evidence of delayed cardiovascular benefit. Fertil Steril. 2005;83:853-854.
47. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004; 291:2959-2968.
48. Mosca L, Manson JE, Sutherland SE, et al. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. Circulation. 1997;96:2468-2482.
49. Subbiah MT. Mechanisms of cardioprotection by estrogens. Proc Soc Exp Biol Med. 1998;217:23-29.
50. Women's Health Initiative Study Group. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized clinical trial. JAMA. 2002;288:321-333.
51. Pulido JS, McConnell JP, Lennon RJ, et al. Relationship between age-related macular degeneration-associated variants of complement factor H and LOC387715 with coronary artery disease. Mayo Clin Proc. 2007;82:301-307.
52. Buch H, Vinding T, la CM, et al. Age-related maculopathy: a risk indicator for poorer survival in women: the Copenhagen City Eye Study. Ophthalmology. 2005;112:305-312.
53. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769-1775.
54. Munaut C, Lambert V, Noel A, et al. Presence of oestrogen receptor type beta in human retina. Br J Ophthalmol. 2001;85:877-882.
55. Ogueta SB, Schwartz SD, Yamashita CK, Farber DB. Estrogen receptor in the human eye: influence of gender and age on gene expression. Invest Ophthalmol Vis Sci. 1999;40:1906-1911.
56. Rakic JM, Lambert V, Deprez M, et al. Estrogens reduce the expression of YKL-40 in the retina: implications for eye and joint diseases. Invest Ophthalmol Vis Sci. 2003;44:1740-1746.
57. Akcay T, Dincer Y, Kayali R, et al. Effects of hormone replacement therapy on lipid peroxides and oxidation system in postmenopausal women. J Toxicol Environ Health A. 2000;59:1-5.
58. Subbiah MT, Kessel B, Agrawal M, et al. Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab. 1993;77:1095-1097.
59. Schuit SC, de Jong FH, Stolk L, et al. Estrogen receptor alpha gene polymorphisms are associated with estradiol levels in postmenopausal women. Eur J Endocrinol. 2005;153:327-334.
60. Boekhoorn SS, Vingerling JR, Uitterlinden AG, et al. Estrogen receptor alpha gene polymorphisms associated with incident aging macula disorder. Invest Ophthalmol Vis Sci. 2007;48:1012-1017.
61. Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125: 279-284.
62. Dewan A, Liu M, Hartman S, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science. 2006;314:989-992.
63. Yang Z, Camp NJ, Sun H, et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science. 2006;314:992-993.
64. Haan MN, Klein R, Klein BE, et al. Hormone therapy and agerelated macular degeneration: the Women's Health Initiative Sight Exam Study. Arch Ophthalmol. 2006;124:988-992.